All In Biotech

NDA 021544 · Teva Branded Pharm

Seasonale

Ethinyl Estradiol, Levonorgestrel · Oral

Last checked: Nov 19, 2026Latest source record: Jan 27, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

Sep 5, 2003

Approved uses

1

Original approval plus efficacy supplements

Registered trials

501

113 Phase 3, 20 recruiting

FAERS reports

419

256 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs, including JOLESSA, are contraindicated in women who are over 35 years of age and smoke [see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 )] . WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See full prescribing information for complete boxed warning. JOLESSA is contraindicated in women over 35 years old who smoke. ( 4 ) Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. ( 5.1 )

What it is approved for

From the label in effect Oct 31, 2024.

JOLESSA ® is indicated for use by females of reproductive potential to prevent pregnancy. JOLESSA is a combination of levonorgestrel, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy. ( 1 )

Mechanism: COCs prevent pregnancy primarily by suppressing ovulation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • SEASONALE · ETHINYL ESTRADIOL 0.03MG; LEVONORGESTREL 0.15MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Ethinyl Estradiol" as an intervention, any sponsor and status, largest first.

All 501 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea39
  • vomiting30
  • drug ineffective28
  • headache22
  • fatigue19
  • pulmonary embolism19
  • abdominal pain16
  • dyspnoea16
  • cholecystitis chronic14
  • dizziness14
  • abdominal pain upper13
  • pruritus13

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20053
200622
200715
20083
200917
201016
201168
201240
201310
201417
201528
201646
201715
201821
201918
202012
202114
202216
202310
20249
202512
20267

Recalls

3 FDA enforcement reports for this application.

  • Mar 15, 2013 · Class III · Terminated

    Failed Impurity/Degradation Specification; an impurity identified as N-Butyl-Benzene Sulfonamide (NBBS) was detected during impurity testing

  • Mar 12, 2013 · Class III · Terminated

    Failed Tablet/Capsule Specifications: This recall is being carried out due to an out of specification result for appearance.

  • Apr 23, 2012 · Class III · Terminated

    Contraceptive Tablets Out of Sequence: This recall has been initiated due to the potential that some regimen packages may not contain placebo tablets.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,069 on PubMed

Sponsor: Teva

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.